Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sibutramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 16/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 16/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 9/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sibutramine SCHEMBL3707643 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL2955 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL16312 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL1598 | 0.98 | CYP3A4 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL6431587 | 0.98 | SLC6A3 (0.97) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL7191483 | 0.98 | CYP3A4 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL7626175 | 0.98 | CYP3A4 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL7189499 | 0.98 | CYP3A4 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL2916993 | 0.98 | SLC6A3 (0.97) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL4594859 | 0.97 | CYP3A4 (0.97) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130355-A1 | Therapeutic agents | KNOLL GMBH (DE) | 2003-07-10 | — | — | US | claimed |
| US-6046242-A | ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF CHLOROBENZENE SUBSTITUTED CYCLOBUTYLALKYLAMINE COMPOUND TO TREAT URINARY INCONTINENCE | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-04 | — | — | US | claimed |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | EPITRACKER INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12427179-B2 | Compositions and methods for diagnosis and treatment of neurodegenerative diseases | Epitracker, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4590287-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY | Brightseed, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250205182-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY | BRIGHTSEED, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250000804-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ANJI PHARMA (US) LLC | 2025-01-02 | — | — | US | disclosed |
| US-20240307336-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | EPITRACKER INC (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240277649-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | EPITRACKER INC (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4410285-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF METABOLIC SYNDROME | Government Of The United States Of America As Represented By The Secretary Of the Navy (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4410380-A2 | DELAYED-RELEASE COMPOSITION COMPRISING BIGUANIDE | Anji Pharmaceuticals Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| US-8344009-B2 | Substituted phenoxy thiazolidinediones as estrogen related receptor-á modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-01 | — | — | US | disclosed |
| US-20120302544-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | BIGNAN GILLES (US) | 2012-11-29 | — | — | US | disclosed |
| US-8263781-B2 | Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-20120108571-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | GAUL MICHAEL (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | US | disclosed |
| US-20080286265-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080221179-A1 | SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-11 | — | — | US | disclosed |
| US-20030130355-A1 | Therapeutic agents | KNOLL GMBH (DE) | 2003-07-10 | — | — | US | disclosed |
| US-6046242-A | ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF CHLOROBENZENE SUBSTITUTED CYCLOBUTYLALKYLAMINE COMPOUND TO TREAT URINARY INCONTINENCE | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | CD4, COL2A1, MMP1 | SLC6A3 1448/4885SLC6A4 3210/4885SLC6A2 2433/4885 |
| US-20250000804-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | SLC5A2, SLC10A1, GPR119 | SLC6A3 788/4885SLC6A4 381/4885SLC6A2 415/4885 |
| US-20030130355-A1 | Therapeutic agents | TPH1, SLC6A2, HTR1A | SLC6A3 20/4885SLC6A4 4/4885SLC6A2 2/4885 |
| US-20250205182-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY | FABP2, VIP, SI | SLC6A3 2081/4885SLC6A4 1221/4885SLC6A2 968/4885 |
| US-20120302544-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, IGF1R | SLC6A3 3283/4885SLC6A4 4049/4885SLC6A2 4231/4885 |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | ESR2, IGF1R, ESRRA | SLC6A3 1957/4885SLC6A4 3224/4885SLC6A2 3374/4885 |
| US-20240277649-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | FABP1, FASN, GPR119 | SLC6A3 1180/4885SLC6A4 652/4885SLC6A2 988/4885 |
| US-20080221179-A1 | SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators | ESR2, ESRRA, ESRRG | SLC6A3 3489/4885SLC6A4 3824/4885SLC6A2 3877/4885 |
| US-20120108571-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, ESRRG | SLC6A3 3155/4885SLC6A4 4124/4885SLC6A2 3732/4885 |
| US-20080286265-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, ESRRG | SLC6A3 3155/4885SLC6A4 4124/4885SLC6A2 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.